Courtemanche Craig F. Jr. 4

4 · PROCORE TECHNOLOGIES, INC. · Filed Jul 14, 2026

AI-generated summary of this filing

Updated Jul 15, 2026

Procore (PCOR) Chairman Craig Courtemanche Exercises Options, Sells Shares

What Happened

Craig F. Courtemanche Jr., Director and Chairman of Procore Technologies (PCOR), exercised 56,122 option-derived shares at $2.42 per share on July 10, 2026 (reported as transaction code M; cost ~$135,815). The same 56,122 shares were then sold in the open market the same day (transaction code S) in two blocks: 42,911 shares at a weighted average ~$43.63 ($1,872,207) and 13,211 shares at a weighted average ~$44.76 ($591,324). Total gross proceeds from the sales were $2,463,531; after paying the exercise cost ($135,815) the cash proceeds were approximately $2.33M (before taxes/fees).

Key Details

Transaction date: July 10, 2026.
Option exercise: 56,122 shares exercised at $2.42 (M) for $135,815.
Open-market sales: 42,911 shares at weighted avg $43.63 ($1,872,207) and 13,211 shares at weighted avg $44.76 ($591,324). Combined proceeds ~$2,463,531.
Sales executed pursuant to a 10b5-1 trading plan dated Dec 9, 2025 (Footnote F1).
Reported weighted‑average price ranges: first block sold between $43.31–$44.235 (F2); second block between $44.31–$45.26 (F3). The filer can provide per‑price breakdown on request.
Some reported holdings/options are held in family/irrevocable trusts (F4–F6); option vesting schedule noted in F7.
Shares owned after the transactions are not specified in the provided filing excerpt — see the full Form 4 for total post‑transaction holdings.
Filing date: July 14, 2026 (transaction was July 10). Form 4s are normally due within 2 business days; this filing was submitted four days after the transaction date.

Context

This was an exercise of options followed by an immediate sale of the resulting shares (effectively a cashless exercise), so the insider did not increase his public holdings as a result of these transactions.
Sales under a 10b5‑1 plan are prearranged trading plans and are generally considered routine; they do not necessarily signal a change in the insider’s view of the company.
Numbers above are from the Form 4; taxes, fees, or other withholdings (if any) are not reflected.

Form 4

Period: 2026-07-10

DirectorOther

Transactions

Exercise/Conversion
Common Stock
2026-07-10$2.42/sh+56,122$135,815→ 975,826 total
Sale
Common Stock
[F1][F2]
2026-07-10$43.63/sh−42,911$1,872,207→ 932,915 total
Sale
Common Stock
[F1][F3]
2026-07-10$44.76/sh−13,211$591,324→ 919,704 total
Exercise/Conversion
Stock Option (Right to Buy)
[F7]
2026-07-10$2.42/sh−56,122$135,815→ 168,366 total
Exercise: $2.42Exp: 2026-11-10→ Common Stock (56,122 underlying)

Holdings

Footnotes (7)

[F1]These shares sold pursuant to a 10b5-1 plan dated December 9, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $43.31 to $44.235, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $44.31 to $45.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]These shares are held by the Craig F. Courtemanche and Hillary Courtemanche Family Trust dated as of November 1, 2012.
[F5]These shares are held by the Courtemanche 2021 Irrevocable Trust UA DTD 6/10/2021.
[F6]These shares are held by The Courtemanche 2016 Irrevocable Trust.
[F7]The shares subject to the option vested in 60 equal monthly installments beginning on the one month anniversary of February 5, 2016, subject to continued service through each applicable vesting date.

Signature

/s/ Benjamin C. Singer, Attorney-in-Fact|2026-07-14

1 file